US and UK Secure Tariff-Free Agreement on Drugs.

Britain and America have reached a landmark trade agreement that will ensure no duties on UK medicine exports being sold in the US market.

The Terms of the Deal

Under the terms of the agreement, the UK has agreed to raise spending on pharmaceuticals through the NHS. This commitment ensures that import taxes on these vital goods will be held at zero for a period of the next three years.

This development follows recent statements to dramatically increase tariffs on branded pharmaceutical imports, with potential rates floated reaching double the cost.

"This deal between the UK strengthens the worldwide climate for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. drug exports," a release said.

Economic Impact

Pharmaceuticals represent one of the the United Kingdom's most significant exports to the United States, which is by far the largest destination for leading British pharmaceutical firms.

Statistics reveal that in the one-year period prior to last September, the UK sold drugs totaling £11.1bn to the US. This value represented nearly one-fifth of British export trade in that period.

"This deal protects employment, stimulates capital expenditure and paves the way for the UK to become a international leader for life sciences," a minister remarked.

Detailed UK Commitments

The deal involves several specific commitments from the UK:

• Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by 25%.
• Boosted Medicine Funding: There is a aim to raise total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
• Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments exceeded twenty percent.

Industry Background

This agreement takes place against a ongoing tension between the drug companies and the UK government over spending levels and approval rates.

These tensions were intensified by claims that US patients were charged significantly more for the same drugs than people in the Britain and the EU.

Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while substantial funding commitments have been pledged toward American operations.

The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had declined as a percentage of its overall budget over the past decade.